Resonant analyzes neuron- and glia-derived cell-free DNA (cfDNA) in the blood to reveal which brain cell types are undergoing degeneration. By resolving these signals to specific cell types—including cortical, dopaminergic, and motor neurons, as well as astrocytes, microglia, and Schwann cells—our assay provides a minimally invasive, systems-level view of neurodegeneration in motion.

This research-use-only (RUO) platform enables scientists to study disease mechanisms, detect early response signals, and advance new strategies for neuroprotective drug development.